August 14, 2025 — Leads & Copy — Lexeo Therapeutics, Inc. (Nasdaq: LXEO) announced business updates across its portfolio and reported second quarter 2025 financial results. The company’s cash, cash equivalents and investments in marketable securities of $152.5 million are expected to provide operational runway into 2028.
R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics, said that the company has made significant progress advancing clinical stage programs and diversifying its pipeline through a strategic partnership. He added that the FDA Breakthrough Therapy designation for LX2006 underscores the potential of this gene therapy candidate.
Business and Program Updates:
LX2006 in Friedreich Ataxia (FA): In July 2025, Lexeo received Breakthrough Therapy designation from the FDA for LX2006 based on interim clinical data. LX2006 has also been selected to participate in the FDA Chemistry, Manufacturing, and Controls (CMC) Development Readiness Pilot (CDRP) program. Lexeo expects final alignment with FDA on the LX2006 registrational study in late Q3 to early Q4 2025. The CLARITY-FA natural history study is currently enrolling and is expected to serve as a concurrent external control arm for the planned registrational study. LX2006 continues to be generally well tolerated with no clinically significant complement activation, and no new treatment-related serious adverse events to report. Lexeo expects to initiate a registrational study in early 2026 with a potential efficacy readout in 2027.
LX2020 in PKP2-ACM: Eight participants have been dosed to date in the HEROIC-PKP2 Phase I/II clinical trial. LX2020 has been generally well tolerated with no clinically significant complement activation, and no treatment-related serious adverse events to date across all dose cohorts. Lexeo expects to share an interim clinical data update in the second half of 2025.
Lexeo closed an $80 million equity financing to further advance development of its clinical stage genetic medicine candidates. In June 2025, Lexeo announced a strategic partnership to develop therapies for genetic cardiac diseases utilizing a novel non-viral RNA platform. Lexeo announced that Louis Tamayo has been appointed Chief Financial Officer.
Second Quarter Financial Results: As of June 30, 2025, cash, cash equivalents, and investments in marketable securities were $152.5 million. Research and Development expenses were $14.7 million for the three months ended June 30, 2025, compared to $16.6 million for the three months ended June 30, 2024. General and Administrative expenses were $16.0 million for the three months ended June 30, 2025, compared to $7.0 million for the three months ended June 30, 2024. Net loss was $26.1 million or $0.60 per share for the three months ended June 30, 2025, compared to $21.2 million or $0.64 per share for the three months ended June 30, 2024.
Contact:
Media: Media@lexeotx.com
Investor: Carlo Tanzi, Ph.D., ctanzi@kendallir.com
Source: Lexeo Therapeutics, Inc.
